News

Kaiser Permanente Research Program on Genes, Environment and Health (RPGEH) and the University of California, San Francisco (UCSF) have been awarded a grant of $24.8m over two years

QRxPharma has reported a contractual agreement with Patheon to manufacture clinical supplies of its controlled release Dual-Opioid formulation – MoxDuoCR. MoxDuoCR is designed to provide 12 hours of

Crescendo Biologics has raised GBP4.5m in a seed-funding led by Sofinnova Partners, to advance the development of its fragment antibody technology platforms. The company claims that the technology

The European Patent Office intends to grant a European patent to Phyton Biotech (Phyton) for its methods of producing taxanes such as paclitaxel. Paclitaxel, the active ingredient in

MDRNA has presented new in vivo data demonstrating continued progress in the advancement of its oncology program. The company reported that MDRNA’s UsiRNAs, delivered by its DiLA2 platform,

GlaxoSmithKline (GSK) has reported the final results from its four-year CombAT (Combination therapy with Avodart and Tamsulosin) study. The results show that combined treatment with Avodart and tamsulosin

NOXXON Pharma (NOXXON) has reported the successful completion of the first phase I trial with its anti-inflammatory Spiegelmer NOX-E36. This drug candidate will be developed for the treatment

Raptor Pharmaceutical (Raptor) has reported positive findings from the completed treatment phase of its open-label phase 2a clinical trial of delayed-release cysteamine bitartrate (DR Cysteamine), in adolescent patients

Arch Pharmalabs (Arch) has entered into a strategic partnership with Orochem Technologies (Orochem) to manufacture a US innovator’s active pharmaceutical ingredient (API) in late-stage clinical development, using Simulated